Beijing SL Pharmaceutical Co.,Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Beijing Shuanglu Pharmaceutical Co., Ltd. (002038) is the first high-tech enterprise in the capital to land on the SME board of the Shenzhen Stock Exchange. Since its establishment in 1994, with its technological advantages and continuous innovation, the company has researched, developed, and launched more than 70 varieties of three national first-class new drugs with independent intellectual property rights. It has won one second prize of the National Science and Technology Progress Award, and nine first, second, and third prizes of the Beijing Science and Technology Progress Award. The company closely focuses on the change of disease spectrum in product research and development, and has rich product reserves in the fields of blood, tumor treatment, cardiovascular and cerebrovascular treatment, liver disease treatment, diabetes treatment, and kidney disease treatment. The company has applied independently as an enterprise four times and received funding from the National "863" Program Fund. The company and Chairman Xu Mingbo have won the "Outstanding Contribution Award" for Zhongguancun's 20th Anniversary Innovation and Development. The company is a key high-tech enterprise under the National Torch Program, one of the first batch of "Hundred Innovative Enterprises" in Haidian Park of Zhongguancun Science and Technology Park, one of the first batch of excellent enterprises under the "Beijing Biomedical Industry Leaping Development Project" (G20 Project), and one of the second phase of key cultivation enterprises; Beijing's "Intellectual Property Pilot Unit" and industrialization base for four national "863" plan achievements, with a national level enterprise technology center. In 2012, Chairman Xu Mingbo was selected as one of the "Top 100 Leading Talents in Science and Technology Beijing". In 2014, Chairman Xu Mingbo was named a technology figure at the Third Capital Science and Technology Festival and a technology figure promoting "Beijing Creation". The company has established a company in the United States to conduct innovative drug research, and has advanced monoclonal antibodies and biopharmaceutical research and production bases internationally. The company's genetic engineering and other products have been successfully exported to nearly 20 countries, steadily advancing the company's internationalization strategy. Shuanglu Pharmaceutical always adheres to the business philosophy of "survival through quality, development through innovation", attaches importance to the human factor in quality management, and adheres to the principles of prevention first, systematic management, customer first, and quality efficiency in quality management. Continuously introducing advanced quality management concepts and quality objectives, implementing comprehensive quality management, and successively obtaining honorary titles such as Quality Management Standardization Unit and Beijing Famous Brand Product. The company's technology center is a nationally recognized enterprise technology center and postdoctoral research workstation. It consists of a molecular biology and biochemistry research room, a chemical drug room, a pilot study room, and a new drug evaluation room. It has a mass spectrometry analysis platform and more than 200 full-time and part-time research and development personnel, of which 60% hold doctoral or master's degrees or medium to senior professional and technical titles. In the past decade, the company has invested more than 10% of its sales revenue in the research and development of its technology center. In recent years, the center has successfully developed dozens of new drugs and gradually pushed them to the market. The company has eight production bases, Changping production base, Daxing production base, and Xinxiang (Cangzhou) raw material drug production base, with a total area of 150000 square meters. The production capacity covers high-tech fields related to biological fermentation, biochemistry, traditional Chinese medicine extraction, chemical raw material drugs, antibodies, and other new pharmaceutical projects, as well as oral solid preparations, water injection, powder injection, and external medication constructed strictly in accordance with international GMP standards A dedicated and comprehensive production line for anti-tumor treatment. The company has been listed as one of the top drug suppliers in the country for many years. At present, the company has become a backbone enterprise in domestic biopharmaceuticals, and is also a steadily growing biopharmaceutical company in the market. |
| Headquarter | Beijing |
| Establish Date | 12/24/1994 |
| Listed Code | 002038.SZ |
| Listed Date | 9/9/2004 |
| Chairman | Xu Mingbo. |
| CEO | Xu Mingbo. |
| Website | www.slpharm.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
